IJDVL Home  

[View FULLTEXT] [Download PDF]  
Year : 2005  |  Volume : 71  |  Issue : 5  |  Page : 311-315

Pityriasis rosea - An update

Antonio Chuh1, Albert Lee1, Vijay Zawar2, Gabriel Sciallis3, Werner Kempf4 
1 Department of Community and Family Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, SAR, Hong Kong S.A.R.
2 Department of Dermatology, NDMVPS Medical College and Research Centre Nashik, Maharashtra, India
3 Department of Dermatology, Mayo Medical School, Mayo Clinic, Rochester, Minnesota, USA
4 Department of Dermatology, University Hospital-Zurich, Zurich, Switzerland

Correspondence Address:
Antonio Chuh
The Bonham Surgery, Shop B5, Ning Yeung Terrace, 78 Bonham Road, Ground Floor
Hong Kong S.A.R.

Recent controversies on the etiology, diagnosis and treatment have led to increased interest in pityriasis rosea (PR). We review these aspects of the disease. PR is universal. The incidence is around 0.68 per 100 dermatological patients, or 172.2 per 100,000 person-years. The prevalence in people aged between 10 and 29 years is 0.6%. The male to female ratio is around 1: 1.43. Evidence on seasonal variation is conflicting, but there is no evidence that the incidence is dependent on mean air temperature, mean total rainfall, or mean relative humidity. Spatial-temporal and temporal clustering of cases of PR has been reported. The association of PR with human herpesvirus-7 infection is still controversial. Owing to the extreme high sensitivities of sequence-based detection methods such as polymerase chain reaction, novel criteria should be applied to evaluate the evidence. There is no evidence that PR is associated with other viral or bacterial infections. The role of autoimmunity in PR warrants further investigations. Many patients with PR have one or more atypical features. Application of validated diagnostic criteria may be helpful for atypical cases. The efficacy of macrolides, including erythromycin, in PR is still under evaluation. There is no evidence that antiviral agents are effective. The efficacies of ultraviolet radiotherapy and systemic corticosteroids are not well established. In managing a patient with PR, we should concentrate more on how the eruption is affecting the quality of life, i.e. the illness, rather than the extent and severity of the eruption, i.e. the disease.

How to cite this article:
Chuh A, Lee A, Zawar V, Sciallis G, Kempf W. Pityriasis rosea - An update.Indian J Dermatol Venereol Leprol 2005;71:311-315

How to cite this URL:
Chuh A, Lee A, Zawar V, Sciallis G, Kempf W. Pityriasis rosea - An update. Indian J Dermatol Venereol Leprol [serial online] 2005 [cited 2021 Jan 22 ];71:311-315
Available from: https://www.ijdvl.com/article.asp?issn=0378-6323;year=2005;volume=71;issue=5;spage=311;epage=315;aulast=Chuh;type=0


Friday, January 22, 2021
 Site Map | Home | Contact Us | Feedback | Copyright and disclaimer